Orion Simdax
Executive Summary
Abbott gains worldwide marketing and distributing rights to injectable congestive heart failure treatment, levosimendan. Orion will manufacture the drug and retain rights in the Nordic countries and certain European territories. Abbott has an option for the oral formulation, which is currently being developed. Orion expects to file an NDA in the second quarter of 1998...
Abbott gains worldwide marketing and distributing rights to injectable congestive heart failure treatment, levosimendan. Orion will manufacture the drug and retain rights in the Nordic countries and certain European territories. Abbott has an option for the oral formulation, which is currently being developed. Orion expects to file an NDA in the second quarter of 1998.... |